Evidence map›Paper›PMID 31290245›Full record

ArticleSmall (Weinheim an der Bergstrasse, Germany)2019

Targeted Drug Delivery to Stroke via Chemotactic Recruitment of Nanoparticles Coated with Membrane of Engineered Neural Stem Cells.

Junning Ma, Shenqi Zhang, Jun Liu, Fuyao Liu, Fenyi Du, Miao Li, Ann T Chen, Youmei Bao, Hee Won Suh, Jonathan Avery and 6 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Small (Weinheim an der Bergstrasse, Germany), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.

0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

65 citing papers in PubMed, 135 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Current advancements in nanotechnology for stem cells.International journal of surgery (London, England) · 2024
    Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review

5 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 2 countries.

Junning MaDepartment of Neurosurgery, Yale University, New Haven, CT, 06511, USA.
Shenqi ZhangDepartment of Neurosurgery, Yale University, New Haven, CT, 06511, USA.
Jun LiuDepartment of Neurosurgery, Yale University, New Haven, CT, 06511, USA.
Fuyao LiuDepartment of Neurosurgery, Yale University, New Haven, CT, 06511, USA.
Fenyi DuDepartment of Neurosurgery, Yale University, New Haven, CT, 06511, USA.
Miao LiDepartment of Neurosurgery, Yale University, New Haven, CT, 06511, USA.
Ann T ChenDepartment of Biomedical Engineering, Yale University, New Haven, CT, 06511, USA.
Youmei BaoDepartment of Neurosurgery, Yale University, New Haven, CT, 06511, USA.
Hee Won SuhDepartment of Biomedical Engineering, Yale University, New Haven, CT, 06511, USA.
Jonathan AveryDepartment of Neurosurgery, Yale University, New Haven, CT, 06511, USA.
Gang DengDepartment of Neurosurgery, Yale University, New Haven, CT, 06511, USA.
Yu ZhouDepartment of Neurosurgery, Yale University, New Haven, CT, 06511, USA.
Peng WuDepartment of Neurosurgery, Yale University, New Haven, CT, 06511, USA.
Kevin ShethDepartment of Neurology, Yale University, New Haven, CT, 06510, USA.
Haijun WangDepartment of Neurosurgery, The First Affiliated Hospital Sun Yat-Sen University, Guangzhou, Guangdong, 510080, China.
Jiangbing ZhouDepartment of Neurosurgery, Yale University, New Haven, CT, 06511, USA.ORCID 0000-0002-1201-5360
Yale University · USSun Yat-sen University · CN

Funding

Systemic gene therapy for glioblastomaR01NS095817 · NINDS · YALE UNIVERSITY · PI ZHOU, JIANGBING · 2016 to 2020
$1.8M
NINDS NIH HHS R01 NS095817
6 · The paper itself

Abstract

Cell membrane coating has recently emerged as a promising biomimetic approach to engineering nanoparticles (NPs) for targeted drug delivery. However, simple cell membrane coating may not meet the need for efficient drug delivery to the brain. Here, a novel molecular engineering strategy to modify the surface of NPs with a cell membrane coating for enhanced brain penetration is reported. By using poly(lactic-co-glycolic) acid NPs as a model, it is shown that delivery of NPs to the ischemic brain is enhanced through surface coating with the membrane of neural stem cells (NSCs), and the delivery efficiency can be further increased using membrane isolated from NSCs engineered for overexpression of CXCR4. It is found that this enhancement is mediated by the chemotactic interaction of CXCR4 with SDF-1, which is enriched in the ischemic microenvironment. It is demonstrated that the resulting CXCR4-overexpressing membrane-coated NPs, termed CMNPs, significantly augment the efficacy of glyburide, an anti-edema agent, for stroke treatment. The study suggests a new approach to improving drug delivery to the ischemic brain and establishes a novel formulation of glyburide that can be potentially translated into clinical applications to improve management of human patients with stroke.

Indexed as

ChemotaxisDrug Delivery SystemsNanoparticlesAnimalsCell MembraneChemokine CXCL12GlyburideHumansMiceNeural Stem CellsReceptors, CXCR4StrokeChemokine CXCL12CXCL12 protein, humanCXCR4 protein, humanGlyburideReceptors, CXCR4CXCR4glyburidenanoparticlesneural stem cellsstroke

Identifiers

PMID31290245
PMCPMC11089900
OpenAlexW2960726587

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.